Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Christine Jean

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6936-289X; OpenAlex author ID A5049731648. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
31
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 9

  1. Decoding the Integrated Stress Response of Pancreatic Cancer: Identifying a Serine-dependent Tumor Subset Under Metabolic Relationships With CAFs. Co-author DOI 10.1002/advs.202515740↗
  2. ATR inhibition potentiates FOLFIRINOX cytotoxic effect in models of pancreatic ductal adenocarcinoma by remodelling the tumour microenvironment. Co-author DOI 10.1038/s41416-024-02904-3↗
  3. Pancreatic cancer orthotopic graft in a murine model. Last author DOI 10.1590/acb382823↗
  4. Pharmacologic Normalization of Pancreatic Cancer-Associated Fibroblast Secretome Impairs Prometastatic Cross-Talk With Macrophages. Co-author DOI 10.1016/j.jcmgh.2021.01.008↗
  5. Translatome-based classification reveals a dual metabolic dependency of a new tumor subtype of pancreatic cancer Co-author DOI 10.1016/j.pan.2021.05.117↗
  6. FAK activity in cancer-associated fibroblasts is a prognostic marker and a druggable key metastatic player in pancreatic cancer. Last author DOI 10.15252/emmm.202012010↗
  7. eIF4A inhibition circumvents uncontrolled DNA replication mediated by 4E-BP1 loss in pancreatic cancer. Co-author DOI 10.1172/jci.insight.121951↗
  8. Focal Adhesion Kinase: A promising therapeutic target in pancreatic adenocarcinoma. Last author DOI 10.1016/j.clinre.2016.10.010↗
  9. Anti-metastatic potential of somatostatin analog SOM230: Indirect pharmacological targeting of pancreatic cancer-associated fibroblasts. Co-author DOI 10.18632/oncotarget.9296↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Corinne Bousquet · 9 shared papers, 2016–2026 · strength 1.09
  2. Stéphane Pyronnet · 7 shared papers, 2016–2026 · strength 0.71
  3. Cindy Neuzillet · 5 shared papers, 2020–2026 · strength 0.69
  4. Yvan Martineau · 6 shared papers, 2016–2026 · strength 0.62
  5. Rémi Samain · 5 shared papers, 2016–2021 · strength 0.41
  6. Rémy Nicolle · 3 shared papers, 2021–2026 · strength 0.41
  7. Sauyeun Shin · 3 shared papers, 2019–2026 · strength 0.39
  8. Juan Iovanna · 2 shared papers, 2021–2026 · strength 0.32
  9. Nelson Dusetti · 2 shared papers, 2021–2026 · strength 0.32
  10. Emilie Decaup · 3 shared papers, 2016–2020 · strength 0.22
  11. Nicolas Alejandro Fraunhoffer · 1 shared paper, 2026 · strength 0.21
  12. Jérôme Raffenne · 2 shared papers, 2021 · strength 0.20
  13. Annemilaï Tijeras‐Raballand · 1 shared paper, 2023 · strength 0.19
  14. Victoire Cardot‐Ruffino · 1 shared paper, 2023 · strength 0.19
  15. Milena Muzzolini · 1 shared paper, 2023 · strength 0.19
  16. Renato Micelli Lupinacci · 1 shared paper, 2023 · strength 0.19
  17. Kévin Bigot · 1 shared paper, 2025 · strength 0.19
  18. Christel Larbouret · 1 shared paper, 2025 · strength 0.19
  19. Pierre‐Emmanuel Colombo · 1 shared paper, 2025 · strength 0.19
  20. Marine Bruciamacchie · 1 shared paper, 2025 · strength 0.19
  21. Jerome F. Cros · 2 shared papers, 2020–2021 · strength 0.18
  22. Richard Tomasini · 2 shared papers, 2020–2021 · strength 0.18
  23. Matteo Ponzo · 1 shared paper, 2021 · strength 0.09
  24. Jérémy Nigri · 1 shared paper, 2021 · strength 0.09
  25. Ilaria Cascone · 1 shared paper, 2021 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.